Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | PYGB | P11216 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518816 | 0.87 | PYGB (0.48) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL11518820 | 0.87 | PYGB (0.48) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL9302995 | 0.83 | CA1 (0.60) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL9302990 | 0.83 | CA1 (0.60) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL16393092 | 0.81 | PYGB (0.53) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL14081291 | 0.78 | ALDH1A1 (0.53) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL25511170 | 0.78 | ALDH1A1 (0.53) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL16217717 | 0.78 | ALDH1A1 (0.53) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL13308253 | 0.77 | PYGB (0.70) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL18934182 | 0.76 | PYGB (0.68) | CA1CA2CA9ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | RTCB, IGF2BP2, SNRPE | CA1 4719/4885CA2 4856/4885CA9 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.